



7-1007

1614

1614

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Application of: Gerard M. Nolan

Serial No.: 10/549,961

Filed: September 16, 2005

Attorney Docket No.: 03-40062-US-1

Examiner: TBD

Group Art Unit: 1614

Title: METHOD AND COMPOSITION
FOR PREVENTING, REDUCING AND
REVERSING OCULAR ISCHEMIC
NEURONAL DAMAGE

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)(3)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The above-identified Applicant submits herewith two references, which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56. Form PTO-1449, attached hereto, lists the references of which Applicant is aware, and which may be material to the examination of this application. Copies of the two above-mentioned references are included with this document.

While the information cited in this Information Disclosure Statement may be "material" pursuant to 37 C.F.R. § 1.56, the filing of these references should not be construed to be an admission that any patent, publication or other information referred to herein is, or is considered to be, either "prior art" for this invention or otherwise material to the patentability of this invention as defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(b) exists.

The references contained in this information disclosure statement were first cited in a European Supplemental Search Report not more than three months prior to the filing of this information disclosure statement.


It is believed that this Information Disclosure Statement is being filed prior to the mailing date of the First Office Action on the merits in the application and pursuant to 37 C.F.R. §1.97(b)(3).

While it is believed that no fee is due in connection with this filing, the Commissioner is hereby authorized to charge any payment of fees or credit any over-payment associated with this application to Deposit Account No. 18-0586.

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.10

EXPRESS MAIL Mailing Label Number: EV 699485025 US
Date of Deposit: July 9, 2007

I hereby certify that this paper and/or fee is being deposited with the United States Postal Service, "EXPRESS MAIL - POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10, on the date indicated above, and is addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450

Laurie A. Drummond
(Name of person mailing paper.)

(Signature of person mailing paper.)

Respectfully submitted,


Nanda P.B.A. Kumar, Esq.
Registration No. 44,853
REED SMITH LLP
2500 One Liberty Place
1650 Market Street
Philadelphia, PA 19103
(215) 851-8100
Attorney for Applicant

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
 (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE



JUL 09 2007 INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT

(37 CFR 1.98(b))

ATTY. DOCKET NO.
 03-40062-US-1

SER. NO.
 10/549,961

APPLICANT

Nolan

FILING DATE

September 16, 2005

GROUP

1614

U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/Subclass	Filing Date
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/Subclass	Translation Yes/No
	BA	WO 03015795 A	27-02-2003	PCT		
	BB					
	BC					

OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	Document Description
	CA	HALPERIN, L. S. et al., "Cystoid Macular Edema Associated With Topical Echothiophate Iodide." Annals of Ophthalmology, December 1993, vol. 25, no.12, (1993-12), pp. 457-458 XP009083264 ISSN: 0003-4886
	CB	
	CC	
	CD	
	CE	

EXAMINER	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Page 1 of 1